Avid Bioservices/CDMO

$6.80

0.89%
-
1D1W1MYTD1YMAX

About Avid Bioservices

Avid Bioservices, Inc. is a contract development and manufacturing organization (CDMO). The Company provides a range of services from process development to Current Good Manufacturing Practices (CGMP) clinical and commercial manufacturing of biologics for the biotechnology and biopharmaceutical industries. It operates in a single segment, which is contract manufacturing and development services. The Company’s services include clinical and commercial product manufacturing, bulk packaging, release and stability testing and regulatory submissions support. The Company also provides a variety of process development services, including upstream and downstream development and optimization, analytical methods development, testing and characterization. It provides fully integrated and customized biomanufacturing services that support its customers from the early preclinical stage to commercial launch and supply.

Ticker

CDMO

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Nicholas Green

Employees

365

Headquarters

Tustin, United States

Avid Bioservices Metrics

BasicAdvanced
$426.23M
Market cap
-
P/E ratio
-$0.18
EPS
1.61
Beta
-
Dividend rate
$426.23M
1.61014
$21.04
$4.07
1.32M
1.354
0.853
81.118
81.882
-3.32%
-2.55%
-6.28%
-3.11%
3.024
2.32
2.321
5.03%
-113.81%
35.72%

What the Analysts think about Avid Bioservices

Analyst Ratings

Majority rating from 5 analysts.
Buy

Price Targets

Average projection from 4 analysts.
80.15% upside
High $16.00
Low $7.00
$6.80
Current price
$12.25
Average price target

Avid Bioservices Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-37.54% profit margin
QuarterlyAnnual
Q2 24
QoQ growth
Revenue
$25.3M
-32.89%
Net income
$-9.5M
375%
Profit margin
-37.54%
608.3%

Avid Bioservices Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 140%
QuarterlyAnnual
Q3 23
Q4 23
Q1 24
Q2 24
Q3 24
Actual
$0.01
-
-$0.03
-$0.15
-
Expected
-$0.04
$0.00
-$0.03
-$0.06
-$0.05
Surprise
-128.57%
-
9.09%
140%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Avid Bioservices stock?

Avid Bioservices (CDMO) has a market cap of $426.23M as of April 15, 2024.

What is the P/E ratio for Avid Bioservices stock?

The price to earnings (P/E) ratio for Avid Bioservices (CDMO) stock is 0 as of April 15, 2024.

Does Avid Bioservices stock pay dividends?

No, Avid Bioservices (CDMO) stock does not pay dividends to its shareholders as of April 15, 2024.

When is the next Avid Bioservices dividend payment date?

Avid Bioservices (CDMO) stock does not pay dividends to its shareholders.

What is the beta indicator for Avid Bioservices?

Avid Bioservices (CDMO) has a beta rating of 1.61. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

What is the Avid Bioservices stock price target?

The target price for Avid Bioservices (CDMO) stock is $12.25, which is 80.15% above the current price of $6.8. This is an average based on projections from 4 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Avid Bioservices stock

Buy or sell Avid Bioservices stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing